Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.48

Mkt cap

4.2M

Volume

501K

High

0.53

P/E Ratio

-0.14

52-wk high

2.92

Low

0.46

Div yield

N/A

52-wk low

0.36

During Tuesday's pre-market session, several health care stocks experienced significant movement. Axcella Health, Tivic Health Systems, Celularity, Shuttle Pharmaceuticals, Comera Life Sciences, and Bionomics saw increases in their share prices, with Axcella Health leading with a 222.2% increase. On the other hand, T2 Biosystems, YS Biopharma, Myomo, Enveric Biosciences, NeuroPace, and Novo Integrated Sciences experienced declines, with T2 Biosystems leading the decline with a 10.7% decrease.

Portfolio Pulse from Benzinga Insights

August 29, 2023 | 1:06 pm

Enveric Biosciences (NASDAQ:ENVB) has been granted a US patent for its lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder. The patent covers compositions and methods for tryptamine-derived prodrugs. The company believes these enhancements could provide a more rapid onset of action and reduced side effects compared to traditional psilocin prodrugs. Enveric is also advancing EVM201 and EVM301 series towards creating innovative alterations to related compounds for treating critical mental health disorders.

Portfolio Pulse from Lara Goldstein

August 28, 2023 | 8:08 pm

Several studies and trials are set to assess the use of psilocybin-assisted therapy for various addictions and pain management. Former NHL player Kyle Quincey is building a psilocybin-assisted therapy center in Colorado. GH Research, Cybin, Enveric Biosciences, Red Light Holland, Incannex Healthcare, and Sunstone Therapies have made significant advancements in their respective programs. The AdvisorShares Psychedelics ETF has seen a consistent lowering trend in its price. GH Research, COMPASS Pathways, Mind Medicine, Bright Minds Biosciences, Enveric Biosciences, Silo Pharma, atai Life Sciences, Incannex Healthcare, FSD Pharma, and Seelos Therapeutics saw varied closing prices.

Portfolio Pulse from Lara Goldstein

August 28, 2023 | 8:07 pm

Enveric Biosciences has been granted Patent No. 11,707,441 by the U.S. Patent and Trademark Office. The patent covers EB-373, a new chemical entity psilocin prodrug being developed by Enveric for the treatment of anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 12:05 pm

The article lists the cannabis stocks that gained and lost on August 24, 2023. Notable gainers include EVIO, Red White & Bloom Brands, and CBD Unlimited. Major losers include Choom Holdings, Radient Technologies, and Target Group.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 9:30 pm

On August 23, 2023, several marijuana stocks experienced significant price movements. Notable gainers included Hemp (OTC:HEMP), 1933 Industries (OTC:TGIFF), and SLANG Worldwide (OTC:SLGWF), while notable losers included Red White & Bloom Brands (OTC:RWBYF), Heritage Cannabis Holding (OTC:HERTF), and CordovaCann (OTC:LVRLF).

Portfolio Pulse from Benzinga Insights

August 23, 2023 | 9:30 pm

The article lists the marijuana stocks that gained and lost on August 22, 2023. The biggest gainers were Red White & Bloom Brands (OTC:RWBYF), Radient Technologies (OTC:RDDTF), and Heritage Cannabis Holding (OTC:HERTF). The biggest losers were EVIO (OTC:EVIO), Choom Holdings (OTC:CHOOF), and Tetra Bio Pharma (OTC:TBPMF).

Portfolio Pulse from Benzinga Insights

August 22, 2023 | 9:30 pm

The cannabis sector experienced mixed performance on August 21, 2023, with several stocks seeing significant gains, while others suffered losses. Notable gainers include Radient Technologies (OTC:RDDTF), Trees (OTC:CANN), and 1933 Industries (OTC:TGIFF), while Red White & Bloom Brands (OTC:RWBYF), CBD Of Denver (OTC:CBDD), and Tetra Bio Pharma (OTC:TBPMF) were among the biggest losers.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 9:30 pm

A recent study by the Federal Reserve indicates that cannabis and psychedelics consumption has reached all-time highs in 2022, particularly among adults aged 35-50. In other news, COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and a potential additional $160 million, while MindMed (NASDAQ:MNMD) has secured a $50 million senior secured credit facility with K2 HealthVentures. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.8 on August 14, slightly below prior openings.

Portfolio Pulse from Lara Goldstein

August 21, 2023 | 2:55 pm

Enveric Biosciences (NASDAQ:ENVB) has completed the manufacturing of its psilocin prodrug, EB-373, enabling the completion of preclinical work. The company will now commence remaining GLP studies to provide data required for human trials. The manufacturing process resulted in a high purity product, allowing Enveric and its partners to handle and ship EB-373 without restrictions for controlled substances. The company expects to complete all remaining preclinical studies required for Human Research Ethics Committee submission in Australia by the end of 2023.

Portfolio Pulse from Vuk Zdinjak

August 21, 2023 | 12:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.